Key facts
- Notable investors include Miracleplus, K2VC, Linear Capital, Danen Capital, Xingkong Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for SynMetabio
- ·The full record, as it builds
Funding rounds
No funding rounds for SynMetabio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SynMetabio
Developer of next-generation sustainable biomaterials designed for synthetic biology. The company offers next generation of biological basic materials through protein design at the genetic level and drought regulation at the species level, thereby enabling clothing companies to reduce environmental pollution during production.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Employees
- 30
- Website
- synmetabio.com/
- Ownership
- Privately Held (backing)
SynMetabio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SynMetabio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SynMetabio in its N-PORT filings yet. We sweep new filings monthly.